Go Pro
→ Gold led me to Mount Rushmore (From Stansberry Research) (Ad)tc pixel Free OCUL Stock Alerts

Ocular Therapeutix (OCUL) Short Interest Ratio & Short Volume

Ocular Therapeutix logo
$10.49 -0.13 (-1.22%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$10.69 +0.20 (+1.90%)
As of 09/11/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

Ocular Therapeutix Short Interest Overview

As of August 31, 2026, Ocular Therapeutix (OCUL) had a short interest of 28.06 million shares sold short, representing 13.18% of the public float. This marks a -1.61% decrease in short interest since the prior report. The short interest ratio (days to cover) is 9.0, meaning it would take 9.0 days of the average trading volume of 2.59 million shares to cover all short positions.

Current Short Interest
28,055,522 shares
Previous Short Interest
28,515,335 shares
Change Vs. Previous Month
-1.61%
Dollar Volume Sold Short
$294.30 million
Short Interest Ratio
9.0 Days to Cover
Last Record Date
August 31, 2026
Outstanding Shares
219,620,000 shares
Short Percent of Float
13.18%
Today's Trading Volume
2,627,723 shares
Average Trading Volume
2,591,759 shares
Today's Volume Vs. Average
101%
Short Selling Ocular Therapeutix?
A Guide To High-Short-Interest Stocks

Sign up to receive the latest short interest report for Ocular Therapeutix and its competitors with MarketBeat's FREE newsletter.

Get Report
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Short Interest History
Short Interest ChartDays to Cover ChartShort Percent of Float Chart

OCUL Short Interest Over Time

OCUL Days to Cover Over Time

OCUL Percentage of Float Shorted Over Time

Ocular Therapeutix Tesla Short Interest History & Recent Changes

Export
Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
8/31/202628,055,522 shares $294.30 million -1.6%13.2%8.96 $10.49
8/14/202628,515,335 shares $286.29 million +6.7%13.4%12.68 $10.04
7/31/202626,735,397 shares $218.43 million -1.1%12.6%13.49 $8.17
7/15/202627,027,521 shares $269.19 million +1.3%12.7%13.07 $9.96
6/30/202626,695,136 shares $262.15 million +0.9%12.6%6.56 $9.82
6/15/202626,456,015 shares $237.84 million +5.5%12.5%11.85 $8.99
5/29/202625,086,045 shares $226.03 million +1.2%11.7%9.04 $9.01
5/15/202624,777,685 shares $226.96 million -0.1%11.6%8.49 $9.16
4/30/202624,793,045 shares $232.31 million +1.1%11.6%8.57 $9.37
4/15/202624,526,963 shares $218.54 million -2.6%11.6%6.99 $8.91
3/31/202625,192,853 shares $213.38 million +6.4%11.9%7.2 $8.47
3/13/202623,683,101 shares $207.46 million +34.2%11.1%3.56 $8.76
2/27/202617,648,381 shares $157.78 million +20.0%8.3%1.44 $8.94
2/13/202614,706,215 shares $130.59 million +27.8%6.9%2.98 $8.88
1/30/202611,506,830 shares $105.17 million -10.0%5.4%2.7 $9.14
1/15/202612,790,655 shares $144.28 million +3.6%6.1%2.21 $11.28
12/31/202512,345,939 shares $149.88 million +16.5%5.9%4.32 $12.14
12/15/202510,593,646 shares $150.11 million -8.9%5.1%2.33 $14.17
11/28/202511,633,800 shares $140.56 million -11.7%5.6%3.8 $12.08
11/14/202513,173,573 shares $148.86 million -4.4%7.7%6.89 $11.30
10/31/202513,773,939 shares $160.60 million +1.4%8.1%6.46 $11.66
10/15/202513,590,000 shares $162.26 million +0.2%8.0%5 $11.94
9/30/202513,560,000 shares $158.52 million -11.3%N/A5.2 $11.69
9/15/202515,280,000 shares $191.61 million +10.4%N/A6.6 $12.54
8/31/202513,840,000 shares $168.99 million +5.8%8.1%5.6 $12.21
8/15/202513,080,000 shares $165.07 million +2.0%N/A5.6 $12.62
7/31/202512,830,000 shares $148.57 million -13.3%7.5%5.6 $11.58
7/15/202514,800,000 shares $164.13 million +4.5%N/A6.8 $11.09
6/30/202514,170,000 shares $131.50 million -1.7%9.1%6.5 $9.28
6/15/202514,420,000 shares $125.89 million +1.1%9.3%7.1 $8.73
5/31/202514,260,000 shares $114.22 million +3.1%9.4%7.9 $8.01
5/15/202513,830,000 shares $99.16 million +6.6%9.1%8.2 $7.17
4/30/202512,980,000 shares $107.73 million -7.9%N/A8.2 $8.30
4/15/202514,100,000 shares $106.17 million +12.0%9.3%9.5 $7.53
3/31/202512,590,000 shares $92.28 million -1.9%8.3%9.1 $7.33
3/15/202512,830,000 shares $99.05 million +6.5%8.5%11 $7.72
2/28/202512,050,000 shares $86.04 million +3.9%7.9%11.6 $7.14
2/15/202511,600,000 shares $84.45 million +6.7%7.6%12.8 $7.28
1/31/202510,870,000 shares $83.70 million -2.6%N/A11.8 $7.70
1/15/202511,160,000 shares $90.73 million +3.9%N/A12.5 $8.13
Gold led me to Mount Rushmore (Ad)

A small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technology. This could be one of the biggest gold finds since the 1870s, yet the stock still trades around 6 dollars. BlackRock and Vanguard have been quietly loading up on shares while most investors have missed the story. The same technology is unlocking hidden resource wealth across America, driving stocks up 227 percent, 378 percent, and even 773 percent.tc pixel

Watch the free video and get the stock name now
12/31/202410,740,000 shares $91.72 million +2.6%N/A10.5 $8.54
12/15/202410,470,000 shares $90.98 million -1.8%N/A9.6 $8.69
11/30/202410,660,000 shares $105.43 million -1.1%N/A9.2 $9.89
11/15/202410,780,000 shares $98.74 million -14.9%N/A9.5 $9.16
10/31/202412,670,000 shares $133.42 million -4.5%N/A11.6 $10.53
10/15/202413,260,000 shares $135.65 million -18.1%N/A11.4 $10.23
9/30/202416,190,000 shares $140.85 million -7.3%N/A13.7 $8.70
9/15/202417,460,000 shares $157.14 million -4.9%N/A12.1 $9.00
8/31/202418,350,000 shares $161.85 million -2.2%N/A11.2 $8.82
8/15/202418,770,000 shares $157.10 million -1.7%N/A10.3 $8.37
7/31/202419,090,000 shares $161.50 million -6.3%N/A9.3 $8.46
7/15/202420,380,000 shares $171.80 million -4.5%N/A8.2 $8.43
6/30/202421,340,000 shares $145.97 million -8.7%N/A8.1 $6.84
6/15/202423,370,000 shares $134.38 million +4.0%N/A9.4 $5.75
5/31/202422,470,000 shares $128.08 million +5.9%N/A9.2 $5.70
5/15/202421,220,000 shares $133.47 million +0.7%N/A8.3 $6.29
4/30/202421,080,000 shares $99.92 million +43.9%N/A7.8 $4.74
4/15/202414,650,000 shares $114.27 million +24.1%N/A6.3 $7.80
3/31/202411,810,000 shares $107.47 million +28.9%N/A5.8 $9.10
3/15/20249,160,000 shares $86.65 million +93.3%N/A4.5 $9.46
2/29/20244,740,000 shares $47.68 million +19.4%N/A2.4 $10.06
2/15/20243,970,000 shares $27.23 million +0.3%N/A2.3 $6.86
1/31/20243,960,000 shares $19.25 million +18.2%N/A2.9 $4.86
1/15/20243,350,000 shares $14.71 million -23.5%N/A2.5 $4.39
12/31/20234,380,000 shares $19.53 million -3.5%N/A3.6 $4.46
12/15/20234,540,000 shares $17.84 million -14.0%N/A3.9 $3.93
11/30/20235,280,000 shares $13.09 million -9.1%7.0%5.9 $2.48
11/15/20235,810,000 shares $13.07 million +22.1%7.7%7.5 $2.25
10/31/20234,760,000 shares $13.57 million +9.4%6.3%6 $2.85
10/15/20234,350,000 shares $10.83 million +6.4%5.8%6.2 $2.49
9/30/20234,090,000 shares $12.84 million -1.7%5.4%5.7 $3.14
9/15/20234,160,000 shares $14.48 million +1.2%5.5%5.2 $3.48
8/31/20234,110,000 shares $15.54 million -16.5%5.5%3.8 $3.78
8/15/20234,920,000 shares $22.19 million -20.3%6.5%4.1 $4.51
7/31/20236,170,000 shares $28.01 million -8.2%N/A5.1 $4.54
7/15/20236,720,000 shares $32.05 million -1.2%N/A5.2 $4.77
6/30/20236,800,000 shares $35.09 million +4.3%N/A5.4 $5.16
6/15/20236,520,000 shares $32.40 million -2.0%N/A5.2 $4.97
5/31/20236,650,000 shares $42.56 million +20.3%N/A6.8 $6.40
5/15/20235,530,000 shares $35.00 million +14.3%N/A5.4 $6.33
4/30/20234,840,000 shares $30.01 million +13.4%N/A3.1 $6.20
4/15/20234,270,000 shares $22.46 million -7.2%N/A2.8 $5.26
3/31/20234,600,000 shares $24.24 million +2.7%N/A3.2 $5.27
3/15/20234,480,000 shares $22.85 million +12.6%N/A3.1 $5.10
2/28/20233,980,000 shares $24.04 million +27.2%N/A2.9 $6.04
2/15/20233,130,000 shares $19.06 million +6.5%4.1%2.4 $6.09
1/31/20232,940,000 shares $11.50 million +4.3%3.9%4.6 $3.91
1/15/20232,820,000 shares $11.28 million -5.1%N/A4.3 $4.00
12/30/20222,970,000 shares $8.35 million -2.3%N/A4.5 $2.81
12/15/20223,040,000 shares $8.42 million +4.1%N/A3.5 $2.77
Gold majors have a big problem (Ad)

Newmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet production stayed at 5.9 million ounces, unchanged from 2020. Newmont, Barrick and Agnico all face the same reserve shortage, pushing majors toward acquiring smaller producing miners. Recent deals show the pattern: Rupert Resources jumped 67 percent and G2 Goldfields jumped 79 percent the day their buyouts were announced. Analyst Garrett Goggin has identified four junior miners he believes are next on the shopping list.tc pixel

See the four junior gold miners flagged as potential buyout targets
11/30/20222,920,000 shares $8.67 million -0.3%N/A3.5 $2.97
11/15/20222,930,000 shares $9.43 million -12.0%N/A3.4 $3.22
10/31/20223,330,000 shares $12.02 million +2.2%N/A3.8 $3.61
10/15/20223,260,000 shares $13.43 million +9.4%N/A3.9 $4.12
9/30/20222,980,000 shares $12.37 million +2.4%N/A3.8 $4.15
9/15/20222,910,000 shares $18.07 million -12.1%N/A5.4 $6.21
8/31/20223,310,000 shares $16.81 million -1.5%N/A6.1 $5.08
8/15/20223,360,000 shares $18.48 million -2.3%N/A6.1 $5.50
7/31/20223,440,000 shares $15.41 million -1.4%4.5%5.7 $4.48
7/15/20223,490,000 shares $15.11 million +3.3%4.6%5.5 $4.33
6/30/20223,380,000 shares $13.59 million -3.7%4.4%5 $4.02
6/15/20223,510,000 shares $12.46 million -11.1%4.6%5 $3.55
5/31/20223,950,000 shares $12.36 million +1.0%5.2%5.9 $3.13
5/15/20223,910,000 shares $12.82 million -2.5%5.1%5.8 $3.28
4/30/20224,010,000 shares $14.32 million -0.3%5.3%6.5 $3.57
4/15/20224,020,000 shares $17.61 million -4.1%5.3%6.5 $4.38
3/31/20224,190,000 shares $20.74 million -9.7%5.5%7.2 $4.95
3/15/20224,640,000 shares $23.76 million -0.6%6.1%7.6 $5.12
2/28/20224,670,000 shares $26.06 million +20.4%6.1%7 $5.58
2/15/20223,880,000 shares $21.65 million +15.8%5.1%5.6 $5.58
1/31/20223,350,000 shares $18.96 million +5.4%4.4%4.4 $5.66
1/15/20223,180,000 shares $19.72 million -0.9%4.2%3.6 $6.20
12/31/20213,210,000 shares $22.37 million -4.5%4.2%2.8 $6.97
12/15/20213,360,000 shares $22.38 million +3.7%4.4%2.9 $6.66
11/30/20213,240,000 shares $22.16 million -13.8%4.3%2.8 $6.84
11/15/20213,760,000 shares $26.62 million -6.7%4.9%3.3 $7.08
10/29/20214,030,000 shares $26.76 million -14.6%5.3%3.7 $6.64
10/15/20214,720,000 shares $52.82 million -9.4%6.2%4.6 $11.19
9/30/20215,210,000 shares $52.10 million -10.6%6.8%6.2 $10.00
9/15/20215,830,000 shares $60.05 million +3.0%7.6%7.6 $10.30

OCUL Short Interest - Frequently Asked Questions

Short interest is the volume of Ocular Therapeutix shares that have been sold short but have not yet been closed out or covered. As of August 31st, investors have sold 28,055,522 shares of OCUL short. 13.18% of Ocular Therapeutix's shares are currently sold short. Learn More on Ocular Therapeutix's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. OCUL shares currently have a short interest ratio of 9.0. Learn More on Ocular Therapeutix's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 13.18% of Ocular Therapeutix's floating shares are currently sold short.

Ocular Therapeutix saw a drop in short interest during the month of August. As of August 31st, there was short interest totaling 28,055,522 shares, a drop of 1.6% from the previous total of 28,515,335 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

13.18% of Ocular Therapeutix's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceuticals" compare to Ocular Therapeutix: Crinetics Pharmaceuticals, Inc. (6.71%), Belite Bio, Inc. Sponsored ADR (3.01%), Lantheus Holdings, Inc. (6.60%), Liquidia Corporation (17.81%), Amneal Pharmaceuticals, Inc. (4.00%), Definium Therapeutics, Inc. (7.50%), Indivior PLC (9.65%), Veradermics, Incorporated (9.63%), Tarsus Pharmaceuticals, Inc. (15.16%), Organon & Co. (6.46%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($62.68 billion), Invesco QQQ ($47.06 billion), iShares Russell 2000 ETF ($23.54 billion), SPDR S&P Biotech ETF ($12.10 billion), Nebius Group N.V. ($9.34 billion), Western Digital Corporation ($8.96 billion), Financial Select Sector SPDR Fund ($8.16 billion), iShares 20+ Year Treasury Bond ETF ($7.98 billion), iShares iBoxx $ High Yield Corporate Bond ETF ($7.52 billion), and VanEck Semiconductor ETF ($7.39 billion). View all of the most shorted stocks.

Short selling OCUL is an investing strategy that aims to generate trading profit from Ocular Therapeutix as its price is falling. OCUL shares are trading down $0.13 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Ocular Therapeutix occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of OCUL, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including OCUL, twice per month. The most recent reporting period available is August, 31 2026.

Understanding short interest metrics can help you assess how traders are positioning around a stock like OCUL:

  • Shares Sold Short: The total number of shares that have been sold by short sellers but have not yet been covered or closed out. A high number may indicate bearish sentiment.
  • Short Float: The percentage of a company’s publicly available shares (or "float") that are sold short. A higher short float suggests a greater portion of the stock is being bet against.
  • Days to Cover (Short Interest Ratio): This estimates how many days it would take short sellers to cover their positions, based on average daily trading volume. Higher values can signal potential for a short squeeze if buying pressure increases.

These metrics are often used by traders to gauge sentiment, volatility risk, and the potential for price movements based on short covering activity.


Related Companies
Short Interest Tools

Short interest data for NASDAQ:OCUL is sourced from the Financial Industry Regulatory Authority (FINRA), with the most recent report published on 9/10/2026. FINRA publishes updated short interest twice a month.
From Our Partners
Why I'm NOT Buying the SpaceX IPO (And What I'm Buying Instead)
Don't buy Nvidia... Not when the AI companies that will define the next decade are selling for pennies. You wo...
Decentralized Masters | Sponsoredtc pixel
Print this before your next trade
Bill Poulos is offering his Smart Trade Options Checklist at no cost today - normally priced at $29.97. It'...
Profits Run | Sponsoredtc pixel
This 38 Dollar Fund Holds Every Major AI Stock and Pays Weekly
The biggest AI stocks like Nvidia, CrowdStrike, and Palantir now trade for hundreds of dollars a share. One fu...
Investors Alley | Sponsoredtc pixel
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
Three under-the-radar companies are already building the infrastructure behind a 200 billion government-backed...
Eagle Publishing | Sponsoredtc pixel
ACTION TAKERS WANTED : Big Elon Opportunity
James Altucher says an FCC filing points to Elon Musk's next major venture, one he believes could dwarf Tesla ...
Paradigm Press | Sponsoredtc pixel